

Lower the pill burden

For your patients suffering from ulcerative colitis with

Pr **OCTASA**[®]
mesalamine
800 mg

THE ONLY 800 mg
DELAYED-RELEASE MESALAMINE
NOW AVAILABLE IN CANADA*¹

OCTASA[®] 800 mg
is indicated for the treatment of moderately active ulcerative colitis.²

CONVENIENT ADMINISTRATION



Orally

⊖ x 6

1x daily

Or in divided doses
At a 4.8 g daily dosing



With or without food



Do not break
the outer coating

Already covered by most provinces[†]

Available for order through your affiliated wholesaler	DIN	UPC	SKU
	02465752	817676020061	2597202053

*Clinical significance has not been established.

†Coverage varies by province. Please check the healthcare plan in your region for more details.

Consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00073064.PDF for important information relating to contraindications, most serious warnings and precautions, adverse reactions, drug interactions, and dosage and administration that has not been discussed in this piece. The Product Monograph can also be obtained by calling **1-888-550-6060** or emailing **medinfo@pharmascience.com**.

References: 1. Health Canada Drug Product Database. Available from: <https://health-products.canada.ca/dpd-bdpp/dispatch-repartition>. Accessed November 21, 2024. 2. Octasa[®] 800 mg Product Monograph. Tillotts Pharma AG. October 25, 2023.



PROUDLY
CANADIAN

